CRO Aptuit has acquired preclinical formulation specialist Kuecept Ltd, the company said. Both companies have extensive experience in respiratory drug delivery.
Kuecept Founder and CEO Mark Saunders commented, “Since our inception in 2007, we have focused our efforts on the provision of flexible, cost effective and responsive preclinical R&D services. Through this acquisition, our customers can now combine our capabilities with Aptuit’s full suite of integrated drug development solutions to facilitate the transition of new drugs through preclinical evaluation to clinical manufacture. Kuecept and Aptuit share a common culture and commitment to scientific excellence, making this a very good fit.”
Aptuit CEO Jonathan Goldman said, “We offer solutions in the fields of integrated drug discovery, CMC and preclinical biosciences. The acquisition of Kuecept enhances our scientific expertise and capabilities in the pre-formulation development space. The addition allows us to improve the transition of compounds from medicinal chemistry in discovery through to formal regulatory based drug product development. Kuecept scientists are skilled in utilizing small milligram quantities of API in the critical de-risking phase of late stage discovery. . . . We expect our customers to benefit from improved solubility solutions, reduced drug attrition and associated reductions in time and development costs.”
Read the Aptuit press release.
